All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
On 25 April, Yucai Wang from Mayo Clinic, Rochester, MN, USA, and colleagues, published in the Journal of the American Medical Association (JAMA) results from a systematic review and meta-analysis1 of adverse events (AEs) associated with the clinical use of programmed cell death ligand 1 (PD-L1) and PD-1 inhibitors.
PD-1 and PD-L1 inhibitors has been widely used to treat various types of cancers, with nivolumab and pembrolizumab (anti-PD-1), as well as atezolizumab, avelumab, and durvalumab (anti-PD-L1) having been approved by the Food and Drug Administration (FDA) for different indications2. Given the widespread use of such inhibitors against cancer, the authors sought to evaluate their safety profile among different pathologies from published clinical trials.
Any grade AE |
Incidence |
95% CI |
---|---|---|
Fatigue |
18.26% |
16.49−20.11 |
Pruritus |
10.61% |
9.46−11.83 |
Diarrhea |
9.47% |
8.43−10.58 |
Grade ≥ 3 AE |
Incidence |
95% CI |
Fatigue |
0.89% |
0.69−1.14 |
Anemia |
0.78% |
0.59−1.02 |
Aspartate aminotransferase (AST) increase |
0.75% |
0.56−0.99 |
Any grade endocrine irAEs |
Incidence |
95% CI |
---|---|---|
Hypothyroidism |
6.07% |
5.35−6.85 |
Hyperthyroidism |
2.82% |
2.40−3.29 |
Hyperglycemia |
1.20% |
0.91−1.55 |
Thyroiditis |
0.75% |
0.52−1.04 |
Adrenal insufficiency |
0.69% |
0.50−0.93 |
Grade ≥ 3 endocrine irAEs |
Incidence |
95% CI |
Hyperglycemia |
0.24% |
0.13−0.38 |
Adrenal insufficiency |
0.18% |
0.10−0.30 |
Type I diabetes |
0.18% |
0.10−0.30 |
Hypohysitis |
0.16% |
0.09−0.27 |
Hypothyroidism |
0.08% |
0.04−0.13 |
Any grade other irAEs |
Incidence |
95% CI |
---|---|---|
Diarrhea |
9.47% |
8.43−10.58 |
AST increase |
3.39% |
2.94−3.89 |
Vitiligo |
3.26% |
2.80−3.79 |
Alanine aminotransferase (ALT) increase |
3.14% |
2.71−3.62 |
Pneumonitis |
2.79% |
2.39−3.23 |
Colitis |
1.24% |
0.99−1.54 |
Grade ≥ 3 other irAEs |
Incidence |
95% CI |
AST increase |
0.75% |
0.56−0.99 |
ALT increase |
0.70% |
0.52−0.93 |
Pneumonitis |
0.67% |
0.50−0.89 |
Diarrhea |
0.59% |
0.45−0.77 |
Colitis |
0.47% |
0.34−0.65 |
This meta-analysis has identified the most common AEs occurring with PD-1 and PD-L1 inhibitors when used for the treatment of various types of cancers in clinical trials. This systematic analysis will aid in the future management of such treatments and provides a useful tool for clinicians.
References
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?